The United States specialty generics market reached a value of US$ 21 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Specialty generic drugs are the generic versions of specialty branded drugs once they lose patent protection. These drugs are used to treat life threatening and serious health conditions such as cancer, autoimmune diseases, epilepsy, HIV, hepatitis, multiple sclerosis, rheumatoid arthritis, etc.

Specialty generics are economical compared to specialty drugs as they don’t need to undergo the costly and time-consuming research and development procedures required for their branded versions. Moreover, marketing and promotional expenses for speciality generics are also lower compared to their branded versions. This results in significant savings for patients, government and healthcare providers. Moreover, the market is also being catalysed by a rising ageing population in the United States. This has resulted in an increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, hepatitis, HIV, autoimmune disease, etc. For instance, the American cancer society estimated a total of 1,762,450 new cancer cases and 606,880 deaths from cancer in the United States for 2019. Additionally, the patent expiration of several blockbuster branded specialty drugs is further expected to catalyse the market growth in the coming years.

Report Scope:

Historical, Current and Future Market Trends

Market Breakup by Route of Administration:

Injectables
Oral
Others

Market Breakup by Therapeutic Application:

Oncology
Hepatitis
Multiple Sclerosis
HIV
Other Autoimmune Diseases
Others

Market Breakup by Distribution channel:

Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies

Competitive Landscape:

The leading players in the US specialty generics industry have also been examined in the report.

Key questions answered in this report:

How has the US specialty generics market performed so far and how will it perform in the coming years?
What is the breakup of the US specialty generics market based on the route of administration?
What has been the impact of COVID-19 on the US specialty generics market?
What is the breakup of the US specialty generics market based on the therapeutic application?
What is the breakup of the US specialty generics market based on the distribution channel?
What are the various stages in the value chain of the US specialty generics industry?
What are the key driving factors and challenges in the US specialty generics market?
What is the structure of the US specialty generics industry and who are the key players?
What is the degree of competition in the US specialty generics market?